Key Details
Price
$80.54Last Dividend
$10.00Annual Revenue
$12.66 BAnnual EPS
$42.08Annual ROE
-467.62%Beta
2.19Events Calendar
Next earnings date:
Feb 12, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 12, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 14, 2023Next split:
N/ARecent split:
Sept 05, 2006Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Lille, le 3 janvier 2025 Avis de mise à disposition du bilan semestriel 2024 du contrat de liquidité du Crédit Agricole Nord de France La Caisse régionale du Crédit Agricole Nord de France annonce avoir mis à disposition du public et déposé auprès de l'Autorité des Marchés Financiers son bilan semestriel du contrat de liquidité contracté avec Oddo Corporate Finance. Le bilan semestriel 2024 du contrat de liquidité peut être consulté sur le site de présentation du Crédit Agricole Nord de France à l'adresse http://communication.ca-norddefrance.fr/ rubrique Publications.
SHANGHAI , Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) in China for KJ-C2219, an allogeneic CAR T-cell therapy, targeting CD19/CD20. The trial will evaluate KJ-C2219 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-ST-01(NCT04581473). This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) in subjects with Claudin18.2 expression-positive, advanced gastric/gastroesophageal junction cancers that have failed at least 2 prior lines therapy.
CAR benefits from strong demand, fleet management and technology investments, which boost profitability. However, lack of dividends and low liquidity pose risks.
Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF). the UK-listed biopharmaceutical company focused on treatments for blood cancers, has entered a collaboration with Kure.ai to develop an ultrafast manufacturing process for its CAR-T cell therapies.
75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December 9, 2024 Best responder duration of response was 31.5 months with complete response ongoing as of December 9, 2024 Conference call to discuss results Tuesday, December 10, 2024 4:30 p.m. ET at https://zoom.us/j/94736340854?pwd=LTBtu2LuvwSb6S6ISuH5yKTDLsI2vt.1 LOS ANGELES, CA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that new NXC-201 NEXICART-1 clinical data in relapsed/refractory AL Amyloidosis has been presented at 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long-.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The data presented include an oral presentation.
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate an encouraging efficacy and safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Most patients in the study received GLPG5101 as a fresh, fit, stem-like, early memory CD19 CAR T-cell therapy, with a median vein-to-vein time of seven days.
FAQ
- What is the primary business of Avis Budget?
- What is the ticker symbol for Avis Budget?
- Does Avis Budget pay dividends?
- What sector is Avis Budget in?
- What industry is Avis Budget in?
- What country is Avis Budget based in?
- When did Avis Budget go public?
- Is Avis Budget in the S&P 500?
- Is Avis Budget in the NASDAQ 100?
- Is Avis Budget in the Dow Jones?
- When was Avis Budget's last earnings report?
- When does Avis Budget report earnings?
- Should I buy Avis Budget stock now?